PA
CLF icon

PharVision Advisers’s Cleveland-Cliffs CLF Stock Holding History

PharVision Advisers’s Portfolio CLF Stock Details CLF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$91K Sell
10,773
-4,454
-29% -$51K 0.92% 57
2025
Q4 		$202K Buy
+15,227
New +$192K 0.1% 550

Other funds holding CLF

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
MRCP
Maple Rock Capital Partners Toronto, Ontario, Canada $3.07B AUM 157.2% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

PharVision Advisers's CLF Position: Q1 2026 in Review

PharVision Advisers reduced its Cleveland-Cliffs (CLF) stake by 29% in Q1 2026, selling an estimated $51K and leaving 10,773 shares worth $91K. The position accounts for 0.92% of the portfolio, ranked #57.

PharVision Advisers first reported a position in CLF in Q4 2025 and has held it in 2 quarters since. The position peaked at $202K in Q4 2025. 566 funds tracked by Wall St. Rank hold CLF as of Q1 2026.

  • PharVision Advisers held 10,773 shares of Cleveland-Cliffs worth $91K as of Q1 2026.
  • PharVision Advisers sold 4,454 Cleveland-Cliffs shares in Q1 2026, an estimated $51K.
  • Cleveland-Cliffs made up 0.92% of PharVision Advisers's portfolio in Q1 2026, its #57 holding.
  • PharVision Advisers first reported a position in Cleveland-Cliffs in Q4 2025 and has held it in 2 quarters since.
  • PharVision Advisers's Cleveland-Cliffs position peaked at $202K in Q4 2025.
  • 566 funds tracked by Wall St. Rank held Cleveland-Cliffs as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.